Ting Xu, Jian Li, Jufeng Wang, Yanhong Deng, Qiu Meng, Zuoxing Niu, Nanfeng Fan, Xianglin Yuan, Jun Deng, Xuefeng Fang, Yanqiao Zhang, Hongqi Tian, Wenbin Liu, Lin Shen. "A phase III, randomized, open-label study of tunlametinib plus vemurafenib versus investigator's choice of therapy in patients with previously treated
                    <i>BRAF</i>
                    <sup>V600E</sup>
                    -mutant metastatic colorectal cancer.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.17_suppl.lba3509